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Abstract Mitochondria, the organelles providing the cell with energy, have 
recently gained greater public visibility in the UK and beyond, through the introduc-
tion of two reproductive technologies which involve their manipulation, specifically 
‘mitochondrial donation’ to prevent the maternal transmission of inherited disorders, 
and ‘Augment’ to improve egg quality and fertility. Focusing on these two ‘Mito-
Technologies’ and mobilising the conceptual framework of “bio-objectification”, we 
examine three key processes whereby mitochondria are made to appear to have a 
life of their own: their transferability, their optimisation of life processes and their 
capitalisation. We then explore the implications of their bio-objectification in the 
bioeconomy of reproduction. Drawing on publicly available material collected in 
two research projects, we argue that mitochondria become a biopolitical agent by 
contributing to the redefinition of life as something that can be boosted at the cel-
lular level and in reproduction. Mitochondria are now presented as playing a key 
role for a successful and healthy conception through the development and promotion 
of MitoTechnologies. We also show how their “revitalising power” is invested with 
great promissory capital, mainly deriving from their ethical and scientific biovalue 
in the case of mitochondrial donation, and from the logics of assetisation, in the case 
of Augment.
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Introduction
Largely unknown only a few years ago, mitochondria1 have recently gained greater 
public visibility in the UK and beyond. The existence of these cellular parts, whose 
metabolic functions are key to the growth and death of the cell, has long remained 
confined to the specialised domain of cytology. However, in recent years, they have 
become increasingly present in a large range of domains including clinical research, 
biomedicine, pharmaceutical and cosmetics industries. Mitochondria have also been 
popularised through genealogical searches and migration studies where mitochon-
drial DNA testing is used to trace maternal ancestry and population origins (Cannell 
2011; Oikkonen 2015). Moreover, a large number of recently published papers have 
shown the crucial role mitochondria play in the development of cancers as well as 
Parkinson disease (Gómez-Sánchez et al. 2016; Kalyanaraman et al. 2018), generat-
ing high hopes in the biomedical field.
Mitochondria are especially becoming increasingly visible and significant in the 
field of reproduction. In the UK, the development and legalisation of new reproduc-
tive techniques, often referred to as ‘three-parent IVF’, brought them to the centre 
of public attention and ethical debates due to the use of genetic material from three 
distinct individuals in order to prevent the transmission of mitochondrial diseases. 
Mitochondria appeared again in the media at the beginning of 2016, when a clinical 
trial was requested for a new reproductive technique seeking to “boost” the “health” 
of old oocytes by changing their “batteries”, i.e. their mitochondria (Connor 2016; 
Knapton 2016). In relation to this, fertility success increasingly seems to be related 
to the mitochondrial DNA itself, as suggested by the development of a new fertility 
test called MitoGrade which measures mitochondrial DNA levels in the embryo in 
order to select those with better chances of implanting in the womb and forming a 
pregnancy (Fragouli et al. 2015; Sample 2015).
The attributes granted to mitochondria have been highlighted and magnified in 
recent years through their circulation in these various domains. This is especially 
noticeable in the number of metaphors emerging to describe mitochondria, such 
as “powerhouse of the cells”, “power generators”, “energy convertor”, “factories”, 
“waste disposal and recycling centre”, “cell battery”, “micromanagers”, “power-
ful liens”, “power packs” or “elixir of life” (Connor 2016; Hamilton 2014; MacRae 
2016; The Economist 2016). Describing metaphorically the roles mitochondria play 
in cellular and metabolic mechanisms, these terms evoke their ‘power’ in relation to 
life. This power seems to work as a double-edged sword, as both a power to support 
1 The term “mitochondria” designates, from a scientific perspective, the organelles situated in the cell 
cytoplasm, whose functions are to produce the energy necessary to its functioning and control the pro-
cesses of cellular growth and death. They possess their own 37 genes which are maternally inherited and 
distinct from the DNA contained in the chromosomes of the cell nucleus.
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life processes and contribute to the health of living organisms, and as participating 
in life’s decay, as a cause of disease. Mitochondria are associated with both fertility 
and infertility, youth and ageing, and with two contrasted dimensions of inheritance; 
positive when it is a source of genealogical identity, and negative when it results in 
the transmission of serious diseases. This illustrates the double dimension of mito-
chondria: as a source of cellular power opening up prospects for regeneration and 
genealogical continuity, and as a vector of genetic malfunctions, disease and decline.
In order to explore the ways mitochondria have become manipulable and under-
stood as source of power which can be used to boost life, we focus on the domain 
of reproduction, which is a unique site in which to question how social and cultural 
understandings of what life is, are transformed, and to explore how human inter-
vention seeks to reconfigure life boundaries towards optimisation. We ask the three 
following questions: (1) Which processes have rendered mitochondria transferable 
and enable their circulation between bodies and domains as if they had a life of their 
own? (2) How does the increasing visibility of mitochondria in the public domain 
and their technologisation transform the understanding of reproductive processes 
and “life itself?” (3) What are the socio-political implications of their circulation in 
the bioeconomy of reproduction?
In order to tackle these questions, we turn to the conceptual framework of “bio-
object” developed by Webster et al., “to refer to socio-technical phenomena where 
we see a new mixture of relations to life or to which ‘life’ can be attributed” (Web-
ster 2012, p. 1). We examine how mitochondria become bio-objects by focusing 
our analysis on two reproductive technologies manipulating mitochondria, that we 
suggest calling MitoTechnologies. The first is the mitochondrial donation technique 
aimed at preventing the transmission of mitochondrial disorders that are caused by 
defects in mitochondrial DNA. The second technology is Augment, a reproduc-
tive technology developed by the US-based company OvaScience, which promises 
to revitalise older eggs by injecting mitochondria taken from immature egg cells. 
While they are both intended to improve conception, the first one targets hereditary 
disease by intervening in the fertilisation process and incorporating external mito-
chondria, while the second targets the aging process affecting the oocyte itself by 
using the woman’s own mitochondria.
Drawing on public material collected in two separate empirical research pro-
jects, we argue that mitochondria, through their bio-objectification, contribute to the 
redefinition of life as something that can be ‘powered’ which we understand both in 
a biological sense as ‘generator of cellular energy’, and in the analytical sense of a 
biopolitical agent of optimisation (Rose 2007). Taking into account these two levels 
of understanding allows us to grasp the political implications of these biological and 
technological transformations. In so doing, the bio-objectification of mitochondria, 
we suggest, challenges current understanding of reproductive processes by adding to 
the fragmentation of gametes and redefining reproductive ageing. Furthermore, we 
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argue that the power of mitochondria to optimise life processes at the cellular level 
is invested with great promissory capital and biovalue aiming at maintaining repro-
ductive promises present in the bioeconomy of reproduction.2 Characterised both by 
the great hopes and expectations associated with reproductive technologies (Kitz-
inger and Williams 2005; Martin et  al. 2008; Mulkay 1993), the market for eggs, 
sperm and reproductive technologies has especially become a lens through which 
to explore the complex dynamics of capitalisation, technologies and the transforma-
tions of meanings and engagements with life itself (Clarke et al. 2010; Waldby 2002; 
Waldby and Cooper 2008).
After discussing the conceptual framework of bio-objectification and situating it 
in relation to the scholarship on bioeconomy and biovalue, we provide a description 
of our methodologies and the material analysed. Focusing on two MitoTechnologies, 
we then examine three key processes whereby mitochondria are made to appear to 
have a life of their own and become bio-objects: their transferability, their transfor-
mation into an agent of revitalisation in reproduction and their capitalisation. We 
end by discussing the implications of their bio-objectification for the bioeconomy of 
reproduction.
Analytical perspectives: bio‑objectification and life itself
In the wake of the Human Genome Project in the nineties and the rapid expansion 
of molecular biology, social scientists have increasingly focused their attention on 
social understandings of ‘what life is’. Expanding on Foucault’s work on biopolitics, 
these authors have considered how understandings of life are transformed when it 
becomes open to technical intervention and reengineering. They have also shown 
how these transformations are part of the biomedicalisation process, characterised 
by a change of scale in medical gaze and types of interventions, from the “external 
nature” to the “internal one” (Clarke et al. 2010). In particular, Rose describes this 
shift as “molecularisation”, defined as “the style of thought of contemporary bio-
medicine [which] envisages life at the molecular level, as a set of intelligible vital 
mechanisms among molecular entities that can be identified, isolated, manipulated, 
mobilised, recombined, in new practices of intervention, which are no longer con-
strained by the apparent normativity of a natural vital order” (Rose 2007, p. 15). 
The objective of these interventions on life is not only to treat pathologies or repair 
body damages but also to maximise body and biological capacities by technoscien-
tific means, in a logic of “optimisation” (Rose 2007) or “enhancement” (Clarke et al. 
2010). Biological processes thus become open to an ever-ending technological opti-
misation, blurring the distinction between disease and normality, but also between 
treatment and enhancement as the purpose of these techniques, as in the case of cos-
metic surgeries or preimplantation genetic diagnosis (PGD), may become unclear 
and subject of discussion.
2 The term “bioeconomy” has been used over the last decade to account for the key role economic and 
neoliberal logics play in the development of new biotechnologies, biomedical knowledge, products, and 
services, and in which life itself is a source of financial and health value (see Clarke 2010; Rose 2007; 
Waldby 2002; etc.).
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Rose insists on the political dimension of these interventions, as they involve 
not only the transferability of molecular elements of life at a technical and biologi-
cal level, but also their “standardisation, regulation, and even ethics” (2007, p. 15), 
which means that life itself becomes open to politics (cultural and social values, 
meanings and norms) in an unprecedented way. In other words, the normativity of a 
natural vital order tends to be substituted by social, cultural and political normativ-
ity. In the field of biotechnologies, ethics has become a pervasive normative domain 
shaping the production of new genetics knowledge and of biological entities. 
Debates on stem cells and nuclear transfer cloning techniques illustrate especially 
well how moral norms shape the development of biologically engineered entities, 
envisioned as technological solutions to political controversies about the frontiers 
of humanity and the value of life, encoding in this way moral values and desirable 
norms in biology itself (Beltrame 2013; Franklin 2001; Testa 2008).
The manipulation, circulation and transformation of the living more broadly take 
part in what has been described as the bioeconomy. This term refers to the capital-
ist logics at work in the transformation of biological tissues, body parts, molecular 
and cellular processes, into commodities. The bioeconomy rests on the production 
of value derived from these biological entities and processes through severing their 
link from their initial environment and capitalising on their biological properties 
(Mitchell and Waldby 2010). Waldby defines the resulting biovalue as “the yield of 
vitality produced by the biotechnological reformulation of living processes” (2002, 
p. 310). In this conceptualisation, the surplus of vitality produced in vivo may lead 
to the production of value through health use, under the form of therapeutic and pre-
ventive potential, but also through exchange, as it may be transferred into commer-
cial profit, the “productivity of tissues [intersecting] with the productivity of markets 
entering into the circuits of national and transnational capital economies” (Waldby 
2014, p. 2). The famous example she discusses is stem cells, a biological product 
turned from waste, like discarded embryos, into a valuable resource whose regenera-
tive properties create biovalue (Waldby 2002).
Taking over and developing further this analytical framework, a number of schol-
ars have explored, analysed and conceptualised the political economies of life itself 
visible in the biotech sector and health industry and their implications for medicine, 
health, and the making of identities, with a burgeoning of related notions such as 
“biocapital” (Rajan 2006), “life as surplus” (Cooper 2011), “promissory capital” 
(Thompson 2005), or “tissue economies” (Mitchell and Waldby 2006). The notion 
of biovalue and its associated concepts have been discussed critically by Birch 
(2017) who proposes a complementary approach. Departing from the importance 
granted to the biological and material, he argues for a better consideration of the 
political-economic actors, knowledges, and practices involved in the creation and 
management of value, such as the biotech firms and stock analysts. Trying to explain 
the apparent paradox of a biotech industry which generates high and rising income, 
even though constantly failing to deliver the services or products it promises to 
develop, he draws attention to the logics of assetisation which he distinguishes from 
the commodification logics favoured in analyses focusing on the biological side of 
the bioeconomy (Birch 2017).
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Some Science and Technology Studies scholars have also attempted to grasp the 
contemporary technoscientific transformations of life through the concept of the 
“bio-object” (Holmberg 2012; Holmberg et  al. 2011; Metzler and Webster 2011; 
Vermeulen et  al. 2016). Although there is no definitive description of bio-objects 
or a list of their intrinsic properties (Metzler and Webster 2011, p. 648), bio-objects 
can be broadly defined as new forms of biological entities, created in the context 
of the laboratory or collected in the clinic, that are transposed into other domains, 
where they acquire new uses, meanings and values. This is the case, for instance, of 
genetically modified organisms or discarded tissues which are ‘revitalised’. It also 
encompasses “entities that we are, by now, much more familiar with but that have 
been brought into new spaces”, such as human gametes or tissue samples stored and 
frozen for future research purposes (Metzler and Webster 2011, p. 649).
The authors in using this conceptual framework insist on the importance of focus-
ing attention on the processes leading to the making of life in different settings in 
order to avoid essentialising biological entities and reducing life to its biological 
understanding. The aim is to trace what they call the “bio-objectification process”, 
wherein “life-forms or living entities are first made into objects, become possi-
ble, through scientific labour and its associated technologies, and then come to be 
attributed with specific identities” (Holmberg et al. 2011, p. 740). This enables us 
to examine how these bio-objects are produced through socio-technical processes 
and are thus not fixed entities. On the contrary, they gain new meanings while they 
circulate in different domains. Furthermore, the manipulation of bio-objects tends to 
blur boundaries between categories—classification, taxonomies—whose distinctive-
ness is taken for granted. ‘Cybrids’, for instance, these embryos made of a human 
nucleus and animal cytoplasm through advanced nuclear transfer techniques, disrupt 
and modify current boundaries between human and non-human through their public 
and parliamentary discussions (Brown 2012; Holmberg 2012).
The study of the bio-objectification processes and their implications are of par-
ticular interest in the domain of reproduction. Indeed, a crucial site where cultural 
and social understandings of life itself have been produced, debated, and reconfig-
ured is the biomedicalisation of reproduction (Franklin and Lock 2003; Strathern 
1992; Thompson 2007). Egg, sperm and embryos not only contribute very materi-
ally to the making of life in the form of children-to-be, but also symbolise life itself 
in Western societies (Franklin et al. 2000). The centrality of reproduction to exist-
ence has turned this domain into a fertile ground to conceptualise how biological life 
becomes open to politics. The ‘biological facts’ have long been thought to provide a 
universal and stable ground to the social organisation of kinship and gender which 
in contrast is thought to be variable historically and culturally. However, the increas-
ing technologisation of biology, especially in the realm of reproduction, has chal-
lenged this taken for granted fixity. It has transformed the common understanding 
of biology or of life itself, and has also opened up a space for public debates about 
the ethics as well as for new biotechnologies as well as for new legal regulation in 
unprecedented ways.
Franklin and Lock (2003), Clarke et al. (2010), Thompson (2005), and Waldby 
and Cooper (2008) have all shown how reproduction plays a central role in the bio-
economy. Indeed, specific properties of reproductive material, especially its (re)
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generative properties are increasingly harnessed for profit, such as in the case of 
stem cells or cloning technologies. Reproduction therefore becomes productive 
(Thompson 2005), despite invisibilising new forms of reproductive labour (Waldby 
and Cooper 2008). The contrasting logics of donation and commodification, their 
tensions and overlapping, in the bioeconomy have been discussed in relation to 
reproductive cells and labour by various scholars (Almeling 2011; Curtis 2010; 
Haimes et  al. 2012; Nahman 2013; Pollock 2003, etc.). However, the conceptual 
framework of bio-objectification as such, which is at the core of our analysis, has 
rarely been used in these works. In contrast, this framework has been used to analyse 
how reproductive material such as placenta (Kroløkke et al. 2018), umbilical cord 
blood (Beltrame 2014) or the embryo (Bock von Wülfingen 2012; Metzler 2012) 
changes ontological status and meaning when redirected into a new life domain, 
but few studies have focused on how reproductive material becomes bio-objectified 
when its purpose remains reproductive, in the sense of making babies and parents. 
Mitochondria provide therefore a unique lens through which to examine the impli-
cations of the “technologisation of life” (Franklin 2013a) in this particular domain. 
In other words, they are a useful and relevant “looking glass” (Franklin 2013b) to 
analyse what happens to life and reproduction, when inner parts of the reproductive 
cell—mitochondria—become transferable and acquire new potentialities within the 
realm of reproduction.
While all bio-objects result from specific and situated processes and are there-
fore singular, Metzler and Webster have pointed out a number of similarities which 
enable them to be considered together analytically to examine “how life enters into 
the picture in new ways and crossing boundaries” (2011, p. 648), opening up “novel 
socio-technical (including political) relations” (Webster 2012, p. 6). In what fol-
lows, we would like to highlight three key features shared by bio-objects, which we 
have identified as especially relevant and useful to track the ways mitochondria have 
become objectified in the field of reproduction.
A first important feature of these bio-objects is their manipulation or technolo-
gisation which allows their transferability. They often are “very tangible objects 
that can be leveraged and stored, as well as circulated and exchanged” (Metzler and 
Webster 2011, p. 649). This implies the capacity, at a material level, to make spe-
cific biological entities which become manipulated through their technologisation. 
The development of genetic editing or nuclear transfer techniques, for instance, has 
enabled the possibility of creating new or hybridised life forms such as transgenic 
crops, crispr/cas9 or human-animal chimeras, by transferring and combining distinct 
biological organisms or material in novel ways (Brown 2012; Chrupek et al. 2012; 
Hansen 2013; Pavone and Martinelli 2015).
Secondly, bio-objects are transposed into new domains or settings in order “to 
know and enhance life—that is bio(s)” by generating and using innovative knowl-
edge (Metzler and Webster 2011, p. 649). Through their objectification, these bio-
logical entities acquire or optimise their potentiality to tame, redirect or control 
life processes, and by doing so challenge and transform the understanding of these 
processes. In other words, the social and cultural meaning, but also the ontology 
of biological material is transformed when they are used in new domains or when 
they acquire new potentialities for medical, research or consummation purposes. 
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For instance, human placenta, which is initially considered as waste, is collected 
and becomes a commodity with supposedly positive virtues for food and cosmetics 
(Brown and Williams 2015; Kroløkke et al. 2018).
A third key feature is the potential for bio-objects to become valuable through the 
promises and hopes they rise in terms of clinical applications or industrial outcomes 
(Beltrame 2014; Vermeulen et al. 2016). Through their manipulation and their circu-
lation across domains, these living biological entities acquire new potentialities and 
uses which can be exploited to generate different types of capital and values, partici-
pating therefore in the bioeconomy. Hauskeller and Beltrame describe, for instance, 
how Umbilical Cord Blood (UCB), collected in the clinic and stored in bio-banks, is 
objectified and acquires present- and future-oriented biovalue by becoming material 
for stem cell research, a valuable life-saving tissue for possible transplants, as well 
as a property (Beltrame 2014: 68; Hauskeller and Beltrame 2016). These authors 
(2016, p. 230) emphasise that “the UCB banking sector is a hybrid of different bio-
economic regimes where redistributive and market economy […], commodification 
and decommodification processes coexist and overlap in complex configurations”. 
These process of value creation, notes Webster, raises specific ethical and legal 
issues and may require renewed regulation or standardisation measures (Webster 
2012), which are necessary for their circulation and transferability, but also more 
broadly for their legitimacy and valuation.
We mobilise these three features for the analysis of our two cases in order to 
describe and examine how the bio-objectification of mitochondria occurs in the use 
and promotion of two particular MitoTechnologies, and what their implications are.
Methods
This paper draws on data collected in two distinct research projects. The first one 
focuses on the use of reproductive technologies in the context of mitochondrial dis-
orders and the other on the production of knowledge on reproductive ageing and 
reproductive technologies aiming at extending fertility. The former project, led by 
Cathy Herbrand, used mitochondrial donation as a lens to explore the interactions 
between scientific progress, policies and patients’ lives. The study involved inter-
views in the UK with women affected by mitochondrial disorders and with key 
stakeholders, including genetic counsellors, clinicians and support group representa-
tives. It also drew on the analysis of various political and media documents, as well 
as on the observation of numerous public and parliamentary debates surrounding 
mitochondrial donation which have taken place between 2013 and 2016 in the UK 
(Herbrand 2017; Herbrand and Dimond 2017). Ethics approval was granted from 
De Montfort University and the London NRES Committee. The second research 
project, led by Nolwenn Bühler explored how knowledge of reproductive ageing 
is produced, shifts, and materialises in reproductive science and medicine, as well 
as the socio-political implications of extending fertility medically in Switzerland. 
The material for this project was collected via in-depth interviews with women or 
couples undergoing reproductive treatment and with experts involved in the field, 
ethnographic observations and a corpus of scientific and medical articles collected 
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through the data bases PubMed, Web of Science and Google Scholar, as well as 
legal and media texts relevant to the Swiss context (Bühler 2016). Ethical approval 
was obtained in September 2011 from the Cantonal Commission of Ethics of 
Research on Humans Beings.
In this paper, only the research data derived from textual sources and public 
debates directly relating to mitochondrial donation and Augment were shared and 
discussed by both researchers. This mainly comprised analysis of a corpus of sci-
entific articles, newspaper articles and opinion pieces, as well as public reports and 
information published online between 2010 and 2016. In addition to initial data col-
lection, further thematic analysis of material available in the public domain before 
2010 and between 2016 and 2018 was jointly conducted in order to trace back and 
follow up recent developments around both techniques.
New MitoTechnologies: powering life?
Drawing on the three key features of bio-objects described above, we trace and ana-
lyse the bio-objectification of mitochondria through their technologisation, their 
reconfiguration, and their valuation, by examining two specific MitoTechnologies. 
We show how mitochondria (1) become a transferable element ‘powering life’, (2) 
enter into and circulate within the domain of reproduction to become an agent of 
revitalisation, and (3) acquire increasing biovalue in the reproductive bioeconomy.
Transferring mitochondria’s vitalising power
One of the key elements in the bio-objectivisation of mitochondria has been the pos-
sibility, at a practical level, to use what is perceived as their vitalising power in other 
human cells by rendering mitochondria transferable. While the role of mitochondria 
in the cell energy production, notably as the site of cellular respiration, has already 
been identified in the 1930s (Ernster and Schatz 1981) and their functioning has 
increasingly become a central object of medical research over the twentieth century, 
new MitoTechnologies and the research which has led to their development have 
taken a major step further by changing the way mitochondria are approached sci-
entifically and by opening up new potential clinical applications. They have ena-
bled the manipulation of mitochondria and the exploitation of its vitalising power 
in unprecedented ways, by making them transferable and thus, usable in other body 
parts.
Early manipulations involving the transfer of mitochondria in humans started 
in the late 1990s when an experimental reproductive procedure called ‘cytoplas-
mic transfer’ was developed in the US to improve the quality of eggs, based on the 
assumption that mitochondria might play a crucial role in fertility (Cohen et  al. 
1997). Although the notion of mitochondria was not explicitly mentioned at that 
time, this technique involved mitochondria transfer through the injection of cyto-
plasm donated by young woman into the patient’s egg, which resulted in the coexist-
ence of two different types of mitochondria within this egg. After being used to help 
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a few dozen of women with infertility problems conceive, this technique was banned 
in 2002 by the FDA when genetic or clinical abnormalities were detected in two 
children (Castro 2016). Whilst this experimental procedure was not so successful in 
terms of reproduction, it enabled a better understanding of infertility and reproduc-
tive ageing mechanisms, as it oriented research to the role mitochondria may play 
in the decline of oocyte quality with age (Pru and Tilly 2001; Tilly 2001). While 
research has continued in this area, public attention waned and interest remained 
confined to the domain of basic research in order to understand the fundamental 
mechanisms of reproductive ageing and somatic ageing more generally.
A few years later however, the existence and the transferability of mitochondria 
were again highlighted in the UK debates on the creation of transspecies hybrids, 
i.e. embryos made of human and animal parts through nuclear transfer. The debates 
taking place around 2007 about the status to give to these hybrids questioned the 
significance and the role of mitochondria and their specific DNA in genetic iden-
tity (Brown 2009). These questions re-emerged and gained even more attention from 
2012, with the discussion and media coverage round a new reproductive technique 
involving mitochondrial transfer as a means to prevent inherited disorders (Con-
nor 2014; Gallagher 2015). In this case, the procedure consists of transferring the 
nucleus of the affected mother’s egg into a healthy enucleated donor egg. In other 
words, the nucleus of the donor egg is replaced by that of the intending mother. The 
newly reconstructed egg containing the mother’s nuclear DNA and the donor’s mito-
chondrial DNA is then fertilised by the chosen sperm in order to create an embryo 
with non-affected mitochondria.
If, technically, the mitochondria remain in their own cytoplasm and the nucleus is 
the one moved, there is a transfer of mitochondria in practice with respect to the final 
outcomes, as the mitochondria of the intending mother’s egg have been replaced. 
This transfer of mitochondria not only occur at a material level but has been explic-
itly emphasised at a discursive level through various visual and rhetorical mecha-
nisms mobilised in the media coverage and the public debates. First, the procedure 
has often been compared to a device whose battery is replaced; the ‘battery’ being 
the frequent metaphor used to designate the mitochondria. These were, for instance, 
the term and the image used by the Wellcome Trust and depictured in a short online 
video to explain what mitochondrial diseases were (Wellcome Trust 2012). Further-
more, naming these techniques ‘mitochondrial donation’ has clearly contributed to 
constructing mitochondria as transferable. Using the term of ‘donation’ is significant 
here, as it refers to organ donation in public imaginary, which involves the collec-
tion and replacement of one body part by another, rather than an intervention at the 
molecular level. This term simultaneously avoid the connotation of commodification 
which could have been perceived as ethically problematic.  Overall, these messages 
confirm and reinforce the notion of mitochondria’s transferability at a discursive 
level. Consequently, through the debates and media coverage of this new reproduc-
tive technique, mitochondria have gained a significant visibility in public imaginary 
and been represented not only as a crucial source of power but also as independ-
ent biological entities which could easily be used and moved around: i.e. establish-
ing their transferability as a key characteristic. At the same time, it is noticeable 
how ethics was already ‘built in’ to this technique by constructing it as an altruistic 
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donation aimed at preventing inheritable diseases, side-lining potentially controver-
sial issues linked to the need for egg provision and the mixing of different types of 
DNA.
One year after the legalisation of mitochondrial donation in the UK, mitochon-
dria made the headlines again, as the authorisation for a clinical trial for the tech-
nology Augment was asked for by a medical team based in Nottingham (Knapton 
2016; MacRae 2016). Augment promises to boost old oocytes or to re-establish 
their efficiency by injecting mitochondria taken from immature eggs, found in 
the ovarian lining and rich in good quality mitochondria, into the cytoplasm of 
mature eggs together with the sperm (ICSI). In newspapers, one could read that a 
new kind of IVF described as “turbocharged” could help older women conceive 
(MacRae 2016), some commentators insisting on the pioneering dimension of the 
technique as “the next IVF revolution” (Connor 2016).
The technique itself was developed and tested by OvaScience, an American-
based company. In media articles, the ‘battery’ metaphor and the boosting or 
energising role mitochondria might play to remediate the age-related loss of qual-
ity of eggs are put forward such as in the following quote:
Augment aims to revitalise old and poor quality eggs by giving them a 
power boost. An egg’s energy comes from mitochondria, tiny ‘battery packs’ 
that weaken with age. OvaScience believes these can be supplemented with 
young, healthy mitochondria taken from a bank of very immature eggs that 
lurk on the edges of a woman’s ovaries. These extra ‘batteries’ should give 
the egg the energy it needs to develop into an embryo (MacRae 2016).
In this case again, the transferability of mitochondria as a source of power is 
put forward, but the origin of the mitochondria is different. While donation from 
a third body is highlighted with mitochondria donation/transfer, it is rather the 
autologous dimension of mitochondria which is emphasised in the case of Aug-
ment, meaning that they come from the same individual. Their transferability is 
presented as a solution that women have inside their body. Indeed, the boosting 
power and regenerative properties of mitochondria come here from the biology 
of the women themselves, their own ‘bank’ as mentioned in the previous quote. 
According to the first couple who have used Augment to conceive a child, this 
was reassuring: “We thought that it was something that was safe, and it was 
almost like the body treating and healing itself. We were very, very excited about 
the opportunity to try it” (Weintraub 2017). Moreover, the regenerative power 
of mitochondria is doubly underlined as one speaks from immature eggs or stem 
cells, already source of new life and regeneration in public imaginary and from 
mitochondria described as the powerhouse and extracted from these immature 
cells. As a consequence, these discourses represent the whole reproductive and 
regenerative process as internal to one woman’s biology, with an empowering 
tint. However, the emphasis on women’s bodies own capacities contributes also 
to counter the ethically controversial potential of the technology in avoiding both 
the mixing of different individuals’ genetic material, and the use of egg donors.
These new Mitotechnologies have made possible the collection of mitochon-
dria as well as their transposition into other cells, which was not previously the 
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case. In other words, mitochondria, through their technologisation, have been 
‘disentangled’ from the cell to which they belonged and can be reincorporated 
in other cellular or body environments. Mitochondria have therefore become 
both ‘manipulable’ and ‘manipulating’, in the sense that they are themselves the 
object of a technical intervention and are used to intervene on other cells or bod-
ies. These biological entities, through their transferability, are thus enacted (Mol 
2002) in different ways, opening up the possibility for them to acquire new uses, 
potentialities and meaning.
Revitalising cells, reconfiguring reproduction?
With the development and the promotion of new technologies involving the trans-
fer of mitochondria, these biological entities have publicly entered the domain of 
reproductive medicine, from which they were previously absent. In this section we 
question the effects of this integration into a new domain, by showing that these 
MitoTechnologies construct gametes and embryos as reproductive cells which can 
be ‘revitalised’ through a transfer of mitochondria, while simultaneously the cell 
boundaries and ‘wholeness’ are challenged. By introducing new ways of boosting 
fertility and preventing inherited diseases, these transfers of mitochondria contrib-
ute to transform current understanding of reproductive processes at two levels: the 
mechanisms of fertilisation themselves, and reproductive ageing limits.
Firstly, mitochondrial donation complicates current understandings of fertilisa-
tion by adding new sequences to the conception of a child. This technique involves 
the fragmentation of the egg or embryo to remove its nucleus and the reconstruction 
of a new egg or embryo. It thus adds a very novel step with respect to processes of 
both IVF (which enables conception outside female body) and with respect to PGD 
(which involves the selection of an embryo but maintains conceived embryos as 
intact). With mitochondrial donation, the egg is divided and reconstructed with an 
external biological component which is supposed to repair it from a medical point of 
view, by replacing the faulty mitochondria with functional and ‘powerful’ ones. This 
provision of mitochondria brings life itself to the egg or embryo. The development 
of mitochondrial donation therefore has implications at the material level, by mak-
ing reproductive mechanisms more complex and transforming reproductive cells, 
but also at the conceptual level, by shifting general understanding of fertilisation 
mechanisms and reproductive cells in public imaginaries. Through the media cov-
erage of mitochondrial donation, it has indeed been repeated frequently that faulty 
mitochondrial leading to miscarriages or ill children are replaced by ‘good quality’ 
or ‘powerful’ mitochondria, enabling a successful pregnancy and a healthy child. 
The egg, and by extension the individual it will constitute, appears to be in need of 
this crucial living energy represented by mitochondria.
The development of Augment introduces another important change in the under-
standing of reproduction, in particular of reproductive ageing, that is the decrease 
of the fertility potential of eggs over a woman’s life time. By adding mitochondria 
from ‘younger’ immature eggs to the ‘older mature egg’, Augment is intended to 
rejuvenate the latter. Underlying this technological development, is the assumption 
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that some eggs and their mitochondria would age, but that some reproductive cells 
– the ovarian stem cells, also called ‘egg precursor cells’, and their mitochondria, 
would be protected from ageing processes and hold a development potential which 
might be redirected towards reproductive purposes. It is the regenerative quality of 
these cells, and especially of their mitochondria, which would be used to rejuvenate 
the former. In other words, a specific spatial and temporal configuration of women’s 
biology emerges, where some kinds of cells situated in a specific location of the 
body would be a source of renewing vitality, while others would be subjected to the 
ineluctable process of ageing, a heterogeneity of times, already identified by Waldby 
(2002) in her work on stem cells.
While still controversial at the scientific level (Bühler 2016), this idea chal-
lenges one of the most entrenched beliefs about reproduction. Indeed, it is gen-
erally taken-for-granted that age-related fertility decline is irreversible both in 
quality and quantity and that the ovarian reserve, i.e. the quantity of oocytes 
contained in ovaries, reaches exhaustion a few years before menopause. How-
ever, the new understanding applied by the Augment technique implies that 
there would be some renewal or regeneration process taking place in the ovaries 
at the adult age (Johnson et al. 2005) and that this regenerative power could be 
used to optimise reproductive processes through the transferability of mitochon-
dria (White et al. 2012), participating in this way to their bio-objectification.
Significantly, the notion of age itself tends to disappear in the marketing dis-
course of this MitoTechnology as reproductive aging is reframed as ‘egg health’. 
While Augment is the result of research on the understanding of the molecular 
biological mechanisms of ageing, it becomes a matter of health that can be opti-
mised through a transfer of mitochondria. This generates the possibility of no 
longer speaking and thinking of age limit, but rather only of a ‘ever better health 
optimisation’ of the reproductive biological material. Like mitochondrial dona-
tion, Augment aims at restoring the level on energy of a damaged egg by trans-
forming it into a ‘healthy egg’, contributing more broadly to blur further the 
distinction between treatment and enhancement (Clarke et al. 2010).
Both technologies construct mitochondria as a key ingredient for a success-
ful and healthy conception in ways that were not previously apparent. In this 
respect, the introduction of a new human biological entity in the reproductive 
process generates a new relationship to reproduction, which becomes understood 
as being ‘powered up’. The MitoTechnologies create a new hybrid: the ‘mito-
enhanced egg’, that is an egg made of mitochondria of different origins or at dif-
ferent ageing stage, which has been ‘revitalised’ or ‘boosted with life’ thanks to 
the input of good quality mitochondria.
These ‘powering up’ processes are highly gendered, at least in two different 
ways, in relation to women’s bodies and their biologies. First, these MitoTech-
nologies convey a negative connotation associated to women’s reproductive bod-
ies and cells in need of being ‘powered up’ by technological means. As Martin 
has shown (1987), women’ bodies and cells are often encapsulated in the meta-
phor of the ‘machine’ and compared to ‘production systems’, ‘mechanical fac-
tories’, etc., converting energy into particular products which play a role in the 
economy of the organism as a whole. Second, the agent of this ‘powering up’ 
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process is itself associated to female attributes as mitochondria and their DNA 
are exclusively transmitted through the maternal line. Both techniques, but also 
by extension women’s bodies, require women’s body material itself to be (re)
boosted but in the case of Augment, this logic is used to promote the technique 
by insisting on the supposed empowering capacity of women’s own mitochon-
dria, enabling them to take control of their ‘faulty reproductive mechanisms’.
Mito‑enhanced eggs in the reproductive bioeconomy: a form of promissory 
capital
Once simple organelles described in biology textbooks, mitochondria, when trans-
ferred and manipulated in MitoTechnologies, become imbued with much promissory 
capital (Thompson 2005). Like other reproductive technologies, they are constructed 
socially and culturally as a desirable solution and promise to repair the disruption 
in the life course created by infertility and to increase the control over reproduc-
tive processes while maintaining some biological connection to the child (Becker 
1994; Franklin 1997). MitoTechnologies indeed generate hope: to have a healthy and 
genetically-related child in the case of mitochondrial donation, or a biological child 
in spite of age-related fertility decline in the case of Augment, both technologies 
thus reinforcing social expectations of biological parenthood. But beyond provid-
ing hope for individuals and promising to improve health and fertility in society, 
MitoTechnologies also raise scientific and economic expectations and investments. 
By increasing the number of reproductive technologies available on the market and 
fuelling their promissory potential, they also nourish the growing business of IVF 
“which is projected to expand from about $10 billion today to $22 billion globally 
by 2020” (Weintraub 2017) and expand the scope of the reproductive bioeconomy. 
Indeed, far more than being increasingly visible in the public imaginary, MitoTech-
nologies become an important stake in the competition for the prestige and the 
financial benefits associated with new scientific discoveries and innovative technolo-
gies. This transformation of a publicly inexistent organelle into a capitalised object 
is a crucial part of their bio-objectification, as we show in this section.
In the case of mitochondrial donation, although public discourses were domi-
nated by a narrative of hope promising to prevent and cure mitochondrial diseases, 
the technologisation of mitochondria has been primarily associated with scientific 
prestige, and less directly with the prospect of improving public health and generat-
ing wealth. Indeed, the prevention of mitochondrial diseases concerns only a limited 
number of persons (Herbrand 2017) and therefore is a niche in the market of repro-
ductive technologies which is unlikely to create important profit.3 What is expected 
from this MitoTechnology is more the valorisation of the national scientific capital 
and the promotion of the UK ethical model, than a financial value as such.
The development and mastering of this cell reconstruction technique by the New-
castle research team has turned this centre into the main pole of expertise in this 
3 Except if mitochondrial donation is used in the future for broader purposes. Some clinicians would 
indeed like to use it, and in some cases said they already have used it, in cases of infertility to increase 
pregnancy rates (Gallagher 2019).
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field. It has therefore enabled the UK to maintain its position as a leader in cutting-
edge scientific and technological innovations. The vote for legalisation of mitochon-
drial donation reflected the recognition and legitimation of this technology, which 
was celebrated as a British scientific accomplishment (Connor 2015). The success 
of mitochondrial donation—e.g. the birth of the first non-affected baby conceived 
via this technique in the UK—would align with previous reproductive achievements 
pioneered by UK scientists (Ridley 2016), such as the first IVF baby or the first 
cloned mammal, and allow the country to stay competitive in the academic mar-
ket, by helping research teams attract further funding, scientific prestige and interna-
tional recognition.
Moreover, the adoption of the law meant that for the first time ever, some type 
of germline modifications on human embryos and gametes were democratically 
authorised and regulated in a permissive but controlled way following a number 
of expert and public consultations (Department of Health 2014). The UK hence-
forth appeared, at the international level, as a pioneer with respect to mitochondrial 
donation regulation and its ethical deliberations. This was apparent in the talk of the 
Chair of the Human Fertilisation and Embryology Authority, Sally Cheshire, when 
she claimed, at a well-attended public conference in London a few months after the 
adoption of the law, that “the UK was the best place for mitochondrial donation” 
as its infrastructures and institutional system “gives people confidence in allowing 
innovation to take place” (Herbrand 2016). More broadly and above all, the 2015 
law confirmed, in line with previous successful liberal IVF and embryo policies, 
the UK position as an ethical model for the discussion and regulation of complex 
biomedical technological innovations through the processes and frameworks which 
were put in place. As Dimond and Stephens show, by “making the technology know-
able, desirable, ethical and sanctionable”, the UK enacted “ethical futures” which 
contribute positively to society in terms of health and economy (2018, p. 132).
The case of Augment is different. While the pioneering dimension of the tech-
nique was also put forward, the altruistic dimension was absent. This MitoTechnol-
ogy was developed by a “global fertility company dedicated to improving treatment 
options for women around the world”—Ovascience,4 which is listed on the stock 
market. Like the other treatments created and commercialised by OvaScience, Aug-
ment is based on the use of the controversial oogonial stem cells identified by Jona-
than Tilly and his team (see among others Johnson et al. 2005, Johnson et al. 2005, 
Skaznik-Wikiel 2009). Tilly, a reproductive biologist, has worked since the end of 
the nineties to understand the molecular mechanisms of reproductive ageing (Tilly 
1996, Morita and Tilly 1999). After more than a decade marked by a controversy 
around the oogonial stem cells he claimed to have identified (Johnson et al. 2005),5 
he founded the company in 2013. The technological process identifying these cells, 
now called Egg Precursor Cells (EggPCSM), were patented, along with treatments 
using them, such as Augment, the “autologous germline mitochondrial energy 
transfer”, in 2012 under several exclusive licenses from the Massachusetts General 
4 See their website: https ://ovasc ience .com/ (consulted in December 2017).
5 For an analysis of the controversy, see Bühler (2016).
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Hospital where Tilly worked as chief of research (Woods and Tilly 2015). The pat-
enting of these techniques and the change of the cells’ name marked an important 
step in their bio-objectification at two levels.
First, it enabled Ovascience to move away from the controversial connotation 
of oogonial stem cells. Their renaming into ‘egg precursor cells’ makes them less 
ethically problematic with respect to the debates and legal regulations about genetic 
manipulation and thus increases their financial value by making them more likely 
to be invested by shareholders. Secondly, the patenting of the egg precursor cells, 
which transforms scientific knowledge and methods into property, capitalises on 
their promissory potential and of the associated treatments, in a for-profit logics. 
The biovalue of these cells results also from OvaScience’s communication strate-
gies. Indeed, the company is listed on the stock exchange and on their website, a 
specific section is intended for investors, showing the importance of the financial 
investments made in these promissory technologies. Financial reports for sharehold-
ers are published online on a regular basis, as well as other relevant news possibly 
impacting on the future of the company, such as the publication of scientific articles 
presenting promissory results or the availability of the technique in a new country 
(McNeely 2015; Waltham 2016).
This bio-objectification of mitochondria in the case of Augment and its promis-
sory capital result from two different kinds of valuation processes. In addition to the 
expected revenue income derived from the prospective reproductive treatments, a 
process of assetisation (Birch 2016) is at play in the creation of these cells’ biovalue. 
While the biological properties of these cells ‘boosted by younger mitochondria’ 
feed into the promissory capital of treatments which are still in development, what is 
also decisive in raising a significant stream of income are the financial strategies of 
value creation. For instance, the strategic management of information which impacts 
the value of the shares on the stock market, as well as the taking over of Ovascience 
by financial analysts and corporate managers, instead of technoscientific actors, 
reflect these processes.
However, while patenting was necessary to the production of biovalue in the 
assetisation logic, it also raised mistrust in the world of reproductive biology and had 
the effect of maintaining the scientific controversy around these cells. In particular, 
the lack of transparency around the technology is considered problematic, as it is not 
possible to reproduce the procedure. Scientific evidence is also still missing (Gos-
den and Johnson 2016; Heindryckx et al. 2015). In addition to the financial issues 
and the several scientific, methodological problems which are regularly criticised by 
experts in the domain (Powell 2007, 2005), the promissory dimension of the tech-
nology itself has become an ethical problem (Heindryckx et al. 2015). The promis-
sory bubble generated by this MitoTechnology is especially criticised by Johnson 
and Gosden, two prominent UK-based figures in reproductive medicine and biology, 
as possibly misleading women wanting their own genetically-related child instead 
of turning to egg donation (Gosden and Johnson 2016). In a way, what makes the 
technology such a profitable investment, and plays an essential role on its stock mar-
ket value—its promissory potential in terms of treatment possibilities—might also 
be what tarnishes and diminishes its biovalue, as it lacks the scientific and ethical 
approval necessary for it to be taken seriously in the scientific community.
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It is interesting to observe that the company has met important financial difficul-
ties as the promissory capital of Augment did not meet the investors and sharehold-
ers’ financial and medical expectations. This led to internal restructuration and a 
resizing of the company leading it to cut half of its workforce at the beginning of 
2018 (Elvidge 2018). In November 2018, OvaScience was then absorbed, through a 
reverse merger,6 by another biotech company Millendo Therapeutics Inc. specialised 
in rare endocrine diseases (Waltham et al. 2018). Even though OvaScience failed to 
fulfil its promise in terms of treatment success and financial growth, this company 
and the technology it developed, like many other IVF technologies, has neverthe-
less played an important role in the reproductive bioeconomy. Augment enabled 
OvaScience to enter the stock market which turned out to be worth of investment 
by another biopharmaceutical company independent of the value of the technology 
itself. It illustrates well the paradox of the life sciences sector which is financially 
rising in spite of its failure to deliver the services and treatments it promises (Birch 
2017). More generally, it also illustrates the considerable financial potential of a 
market for reproductive technologies targeting reproductive ageing in societies anx-
ious about the postponement of family building and related fertility decline.
Conclusion
While the bio-objectification of regenerative stem cells has been thoroughly studied, 
this analysis adds to this body of scholarship by documenting how the process of 
bio-objectification occurs in the case of mitochondria and more broadly in the field 
of reproduction. Focusing on two reproductive technologies using mitochondria, we 
have shown how these organelles are built and perceived as ‘powering life’ or as a 
‘life booster’. Their technologisation renders them transferable and gives them the 
status of an autonomous bodily entity. Moreover, through their transferability, they 
become technologies themselves used to enhance, optimise or revitalise reproduc-
tion. Unlike other bio-objects, such as aborted foetal tissue or umbilical cord blood, 
mitochondria are not part of a waste circuit and their bio-objectification does not 
depend on the regenerative properties of discarded tissue, transforming it into a val-
uable good. Their bio-objectification rests rather on their physiological properties 
in regard to cellular metabolism—their function as ‘batteries’—which, when trans-
ferred to another body or another body part, potentialise fertility and reproductive 
cells by playing a repairing and enhancing role.
Made possible at a technical level, their transferability was also put forward in 
public discourses about mitochondrial donation. Mitochondria were inscribed in a 
narrative of donation from a healthy donor to couples and families struggling with 
genetic disorders and wanting to prevent transmission of disease to their child. In 
6 A financial operation which allows Millendo to access the stock market. It is therefore not the patented 
technologies by OvaScience, the MitoTechnology Augment, which is valued by this new company, but 
the entry into stock exchange Augment allowed to make (for more information, see: DeAngelis 2018 or 
Meiling 2018).
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contrast, in the case of Augment, we have shown that it was the internal nature of 
mitochondria’s transferability which was highlighted, the idea that mitochondria 
can easily be transferred between different cells and tissues within the same body. 
Instead of an altruistic transfer from one person to another, in the second case, it is 
the genetic continuity and the idea that the whole process, though mediated tech-
nologically, takes place inside one women’s body which is highlighted. While the 
processes differ, in both cases MitoTechnologies are developed and presented as 
technological solutions which are ethically neutral or positive. In this respect, mito-
chondrial donation was contrasted as an ethical project in itself in the UK context, 
whereas augment development is inscribed in a search to circumvent legal and ethi-
cal constraints. In other words, they both exemplify how the development of bio-
objects is shaped by ethical concerns, what is considered morally good and desirable 
becoming very materially inscribed in biology itself as shown in our analysis.
Through the development and promotion of MitoTechnologies,—technologies 
which both use mitochondria and transform them in technologies—these orga-
nelles have entered the domain of reproduction as appearing to play a key role for 
a successful and healthy conception. Not only have their existence and presumed 
functions become visible and praised, but mitochondria can now also be actively 
manipulated in order to optimise reproduction in highly novel ways. While other 
reproductive technologies have been developed to improve the fertilisation process 
or avoid inherited diseases, MitoTechnologies are characterised by another type of 
intervention. Unlike PGD, PGS, ICSI or medical abortion, which are about select-
ing (or discarding) particular gametes, embryos or foetuses, MitoTechnologies inter-
vene directly on the cellular processes themselves in order to optimise fertilisation. 
Moreover, these technologies are characterised by seeking to act on reproduction as 
far upstream as possible. Indeed, they intervene directly on the reproductive gametes 
or immediately after fertilisation takes place. Thus, in contrast with other pre-con-
ception, preimplantation or prenatal technologies, the temporal dimension of Mito-
Technologies, combined with the microcellular site of intervention, is what makes 
MitoTechnologies unique.
Mitochondrial donation aims to restore the cell power and make it work correctly 
through the transfer of ‘healthy’ mitochondria, in order to increase the chances of 
having a child whose metabolism and body functions work correctly. In the case 
of Augment, instead of mitigating age-related fertility decline by substitution—egg 
donation—or time suspension—egg freezing—Augment intervenes directly on the 
ageing process rather than on its result. Both MitoTechnologies seek to optimise the 
cells and the cellular processes, and more broadly, the reproductive process itself 
(fertility), through the transfer of good mitochondria, this ‘life fuel’. Through their 
technologisation, transferability and ability to ‘power life’, mitochondria reconfig-
ure the notion of life, particularly as it relates to reproduction. Bio-objectification 
in reproduction is especially significant as it affects life at different levels: cellular, 
individual, and population. Mitochondria become thus a revitalising and biopolitical 
agent by ‘powering life’ not only inside the cells themselves but also by promising 
to assist the development of new human lives, in response to biopolitical concerns 
about the health and size of the population.
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More than that, the bio-objectification of mitochondria reconfigures social and 
cultural understandings of reproduction. Firstly, mitochondria complicate scien-
tific and popular understandings of fertilisation by challenging the cell boundaries 
and the wholeness of the egg, which can now be decomposed and recomposed by 
assembling its different parts. Secondly, they transform the current understand-
ings of reproductive ageing as an ineluctable decline, into ‘egg health’, which, 
in contrast, conveys the idea of a technologically ever-optimisable biology. As 
part of this bio-objectification process, a new hybrid entity made of mitochondria 
from a different genetic origin and state of maturation (or ageing) is created, an 
entity that we call the mito-enhanced egg. In contrast with regular oocytes, these 
eggs are expected to function as ‘better’ or ‘healthier’ reproductive cells reinforc-
ing in this way their revitalising role.
Finally, our analysis has shown how the ‘life powering’ properties of mito-
chondria and the promise of optimisation become part of the bioeconomy of 
reproduction. The two cases show how the promissory potential of these Mito-
Technologies play not only a key role in creation of economic capital, but also 
of a scientific and ethical capital, illustrating the embedded character of related 
financial, knowledge and moral economies. While both technologies have seen 
investments as innovations, the first reflects the public service and the use of bio-
ethics to increase its legitimacy as well as to reinforce the UK’s leading posi-
tion in the biotech sector; the second illustrates the functioning and dynamics of 
private (for profit) sector interests where in addition to the future-oriented com-
modity-based value of the technique, an asset-based value is created through its 
patenting. As new reproductive technologies of hope, they also contribute to the 
expansion and maintenance of a market in reproduction, by increasing the range 
of reproductive technologies available and promoting the idea that reproduction is 
biologically and technologically optimisable.
Overall, the bio-objectification of mitochondria contributes to disconnecting 
these cell organelles not only from their body environment but also from their social 
and political dimensions. The effort put into the development of these technolo-
gies and the attention they have attracted reflect, more broadly, how social, medi-
cal and ethical problems are increasingly addressed by intervening at the cellular 
level, rather than in the social and political sphere. Focusing on mitochondria and 
singling them out as both a source of fertility problems and their technological solu-
tion present a convenient and profitable way of responding at the individual level 
to much broader complex social, political and moral questions. MitoTechnologies 
and the discourses which promote them tend to obscure other interrelated complex 
ethical and economic issues; this includes the material and human resources needed 
for their development (e.g. the need for significant egg provision), their cost-effec-
tiveness compared to existing alternatives, the emphasis put on biological related-
ness, and the potential to improve health in society, or to increase health disparities 
by benefiting only a small group of privileged individuals. A detailed and critical 
analysis of their development and applications is therefore significant and timely.
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